Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics Inc (TNYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 234,773
  • Shares Outstanding, K 166,506
  • Annual Sales, $ 0 K
  • Annual Income, $ -111,130 K
  • EBIT $ -97 M
  • EBITDA $ -89 M
  • 60-Month Beta 3.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.71

Options Overview Details

View History
  • Implied Volatility 201.78% (-39.59%)
  • Historical Volatility 102.75%
  • IV Percentile 24%
  • IV Rank 16.06%
  • IV High 862.56% on 11/20/25
  • IV Low 75.34% on 01/07/25
  • Expected Move (DTE 12) 0.3995 (28.33%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 317
  • Volume Avg (30-Day) 409
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 20,138
  • Open Int (30-Day) 26,863
  • Expected Range 1.0105 to 1.8095

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 6
  • High Estimate -0.11
  • Low Estimate -0.22
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +22.61%
on 11/20/25
1.5600 -9.62%
on 11/12/25
+0.0300 (+2.17%)
since 11/05/25
3-Month
1.1500 +22.61%
on 11/20/25
2.3500 -40.00%
on 10/10/25
+0.0600 (+4.44%)
since 09/05/25
52-Week
0.3600 +291.67%
on 05/13/25
4.0100 -64.84%
on 12/10/24
-1.9100 (-57.53%)
since 12/05/24

Most Recent Stories

More News
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201...

TNYA : 1.4100 (+2.17%)
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAKâ„¢-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses...

TNYA : 1.4100 (+2.17%)
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results  from the MyPEAK ™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second...

TNYA : 1.4100 (+2.17%)
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 1.4100 (+2.17%)
Piper Sandler Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tenaya Therapeutics, with a price target of $40.00. The company’s shares closed yesterday at $1.77.Elevate Your...

TNYA : 1.4100 (+2.17%)
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 1.4100 (+2.17%)
Healthcare's Convergence Accelerates as Aging Demographics Meet Breakthrough Therapies

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – America's chronic disease burden has reached $4.9 trillion in annual healthcare expenditures, driven by...

VKTX : 38.55 (-0.05%)
LXRX : 1.4000 (-1.41%)
IOVA : 2.20 (unch)
AVAI : 0.2875 (-2.58%)
TNYA : 1.4100 (+2.17%)
CI : 265.44 (-1.11%)
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 1.4100 (+2.17%)
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 1.4100 (+2.17%)
Tenaya Therapeutics Presents Interim Data from MyClimbâ„¢ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM ...

TNYA : 1.4100 (+2.17%)

Business Summary

Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company's product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH...

See More

Key Turning Points

3rd Resistance Point 1.4933
2nd Resistance Point 1.4567
1st Resistance Point 1.4333
Last Price 1.4100
1st Support Level 1.3733
2nd Support Level 1.3367
3rd Support Level 1.3133

See More

52-Week High 4.0100
Fibonacci 61.8% 2.6157
Fibonacci 50% 2.1850
Fibonacci 38.2% 1.7543
Last Price 1.4100
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar